Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Imatinib Mesylate 17Cytarabine 13Azacitidine 13Cyclophosphamide 11Decitabine 9Dasatinib 9Etoposide 8nilotinib 7Peripheral Blood Stem Cell Transplantation 7Busulfan 7Tacrolimus 6Polymerase Chain Reaction 6Idarubicin 6Antilymphocyte Serum 6fludarabine phosphate 5Mycophenolic Acid 5Melphalan 5Blood Specimen Collection 5ruxolitinib 4pegaspargase 4fludarabine 4Whole-Body Irradiation 4Radiotherapy 4Methylprednisolone 4Hydroxyurea 4Filgrastim 4ponatinib 3Surveys and Questionnaires 3Rituximab 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × guadecitabine × Myeloid × Clear all
NCT03454984 2018-11-15

SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation

Groupe Francophone des Myelodysplasies

Phase 2 Unknown
40 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡